Unknown

Dataset Information

0

Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.


ABSTRACT: A semiquantitative 123I-metaiodobenzylguanidine (123I-MIBG) scoring method (the Curie score, or CS) was previously examined in the Children's Oncology Group (COG) high-risk neuroblastoma trial, COG A3973, with a postinduction CS of more than 2 being associated with poor event-free survival (EFS). The validation of the CS in an independent dataset, International Society of Paediatric Oncology European Neuroblastoma/High-Risk Neuroblastoma 1 (SIOPEN/HR-NBL1), is now reported. Methods: A retrospective analysis of 123I-MIBG scans obtained from patients who had been prospectively enrolled in SIOPEN/HR-NBL1 was performed. All patients exhibited 123I-MIBG-avid, International Neuroblastoma Staging System stage 4 neuroblastoma. 123I-MIBG scans were evaluated at 2 time points, diagnosis (n = 345) and postinduction (n = 330), before consolidation myeloablative therapy. Scans of 10 anatomic regions were evaluated, with each region being scored 0-3 on the basis of disease extent and a cumulative CS generated. Cut points for outcome analysis were identified by Youden methodology. CSs from patients enrolled in COG A3973 were used for comparison. Results: The optimal cut point for CS at diagnosis was 12 in SIOPEN/HR-NBL1, with a significant outcome difference by CS noted (5-y EFS, 43.0% ± 5.7% [CS ? 12] vs. 21.4% ± 3.6% [CS > 12], P < 0.0001). The optimal CS cut point after induction was 2 in SIOPEN/HR-NBL1, with a postinduction CS of more than 2 being associated with an inferior outcome (5-y EFS, 39.2% ± 4.7% [CS ? 2] vs. 16.4% ± 4.2% [CS > 2], P < 0.0001). The postinduction CS maintained independent statistical significance in Cox models when adjusted for the covariates of age and MYCN gene copy number. Conclusion: The prognostic significance of postinduction CSs has now been validated in an independent cohort of patients (SIOPEN/HR-NBL1), with a postinduction CS of more than 2 being associated with an inferior outcome in 2 independent large, cooperative group trials.

SUBMITTER: Yanik GA 

PROVIDER: S-EPMC5868501 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.

Yanik Gregory A GA   Parisi Marguerite T MT   Naranjo Arlene A   Nadel Helen H   Gelfand Michael J MJ   Park Julie R JR   Ladenstein Ruth L RL   Poetschger Ulrike U   Boubaker Ariane A   Valteau-Couanet Dominique D   Lambert Bieke B   Castellani Maria-Rita MR   Bar-Sever Zvi Z   Oudoux Aurore A   Kaminska Anna A   Kreissman Susan G SG   Shulkin Barry L BL   Matthay Katherine K KK  

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20170908 3


A semiquantitative <sup>123</sup>I-metaiodobenzylguanidine (<sup>123</sup>I-MIBG) scoring method (the Curie score, or CS) was previously examined in the Children's Oncology Group (COG) high-risk neuroblastoma trial, COG A3973, with a postinduction CS of more than 2 being associated with poor event-free survival (EFS). The validation of the CS in an independent dataset, International Society of Paediatric Oncology European Neuroblastoma/High-Risk Neuroblastoma 1 (SIOPEN/HR-NBL1), is now reported.  ...[more]

Similar Datasets

| S-EPMC8791815 | biostudies-literature
| S-EPMC5747549 | biostudies-literature
| S-EPMC7072500 | biostudies-literature
| S-EPMC10511015 | biostudies-literature
2009-06-25 | GSE11877 | GEO
2009-06-25 | E-GEOD-11877 | biostudies-arrayexpress
| S-EPMC7936051 | biostudies-literature
| S-EPMC2254538 | biostudies-literature
| S-EPMC9589152 | biostudies-literature
| S-EPMC3463166 | biostudies-literature